SCHEMBL5535896

SCHEMBL5535896

O=[C]OCc1coc2cc(Br)ccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
ALOX15 P16050 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PIM1 P11309 1/20 0.35
ALDH1A1 P00352 3/20 0.34
GAA P10253 2/20 0.34
PKM P14618 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
PTPN1 P18031 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
HTT P42858 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HPGD P15428 1/20 0.33
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
TTR P02766 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536452 0.88 PTPN1 (0.43) MAPTSMN1; SMN2PIM1ALDH1A1GAA
SCHEMBL5546148 0.82 CYP11B1 (0.46) MAPTALOX15SMN1; SMN2PIM1ALDH1A1
SCHEMBL5543815 0.82 MAPT (0.36) MAPTALOX15SMN1; SMN2PIM1GAA
SCHEMBL1530595 0.75 MAPT (0.39) MAPTALOX15SMN1; SMN2PIM1ALDH1A1
SCHEMBL17378987 0.74 MAPT (0.38) MAPTALOX15SMN1; SMN2PIM1ALDH1A1
SCHEMBL15897810 0.73 CSNK2A1 (0.46) MAPTALOX15SMN1; SMN2PIM1ALDH1A1
SCHEMBL5537157 0.73 HTR1A (0.35)
SCHEMBL5536051 0.73 PTPN1 (0.43) KMT2APTPN1HTTKDM4E
SCHEMBL5544888 0.73 LOXL2 (0.33)
SCHEMBL6602034 0.72 PYCR1 (0.40) MAPTALOX15SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885ALOX15 2847/4885SMN1; SMN2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.